National Vaccine Program Office

The 1st International Neonatal Vaccination Workshop, March 2 - 4, 2004

Program of Events

Tuesday, March 2, 2004

Speakers

7:00 am

Registration
Poster viewing throughout the day

Session 1:
Impact of infectious disease in early life: rationale for neonatal vaccination

Larry Pickering, M.D.
Trudy Murphy, M.D.

8:30 am

The challenge: the impact of infectious diseases in early life on child health in developing and industrialized countries and rationale for expanded neonatal immunization

Paul-Henri Lambert, M.D.

9:00 am

The developing immune system and neonatal immunization: an overview

Claire-Anne Siegrist, M.D.

9:30 am

US FDA regulatory considerations for assessing safety, immunogenicity, and efficacy

Karen Farizo, M.D.

10:00 am

Break

Session 2:
Experience with the immunogenicity and efficacy of vaccines licensed for newborns

Stanley Plotkin, M.D.

10:15 am

Poliovirus vaccines, oral and inactivated

Stanley Plotkin, M.D.

10:45 am

Hepatitis B vaccine

Anthony Fiore, M.D.

11:15 am

BCG and its immunomodulatory effects

Martin Ota , M.D., Ph.D.

11:45 am

Discussion

12:15 pm - 1:15 pm

Lunch

Session 3:
Prospects for neonatal vaccination against pertussis

Claire-Anne Siegrist, M.D.

1:15 pm

Infant immune responses to pertussis infection and vaccines

Francoise Mascart, M.D., MPH

1:45 pm

Clinical experience with neonatal DTwP vaccine

Peter McIntyre, M.D., Ph.D., FRACP, FAFPHM

2:15 pm

Clinical experience with neonatal DTaP vaccine

Cesare Belloni, M.D.

2:45 pm

Comparison of potential vaccination strategies to decrease infant pertussis (maternal, "cocooning," and neonatal)

Kathryn Edwards, M.D.

3:15 pm

Discussion

3:45 pm

Break

Session 4:
Immunogenicity and efficacy of polysaccharide and polysaccharide-protein conjugate vaccines in neonates

David Goldblatt, M.D.

4:00 pm

Alternative strategies for neonatal protection against Haemophilus influenzae type b and pneumococcus, including maternal immunization

Mathuram Santosham, M.D.

4:30 pm

Accelerating immunity to Haemophilus influenzae type b in the first six months of life

Dan Granoff, M.D.

5:00 pm

The antibody response to capsular polysaccharide antigens

Alexander Lucas, Ph.D.

5:30 pm

Pneumococcal vaccine in the newborn

David Goldblatt, M.D.

6:00 pm –
6:30 pm

Discussion

Wednesday,March 3, 2004

Speakers

7:00 am

Registration
Poster viewing throughout the day

Session 5:
Prospects for prevention of viral infections in early life

Ann Arvin, M.D.

8:00 am

Live attenuated RSV and parainfluenza virus vaccines

James Crowe, Jr., M.D.

8:30 am

Immunity to rotavirus infection and rotavirus vaccines

Timo Vesikari, M.D.

9:00 am

Immunogenicity of measles vaccine in infants with and without passive antibodies

Hayley Gans, M.D.

9:30 am

Protecting neonates through immunization of mothers: experience with influenza and respiratory syncytial virus

Janet Englund, M.D.

10:00 am

Discussion

10:30 am

Break

Session 6:
Strategies for protecting neonates through maternal and/or neonatal vaccination

Fran Rubin, Ph.D.
Ann Arvin, M.D.

10:45 am

Herpes viruses: CMV and HSV

Ann Arvin, M.D.

11:15 am

Group B streptococcus

Carol Baker, M.D.

11:45 am - 12:45 pm

Lunch

12:45 pm

Passive antibody to HIV in neonates (primate model)

Ruth Ruprecht, M.D., Ph.D.

1:15 pm

Immune response to HIV in neonates

Katherine Luzuriaga, M.D.

1:45 pm

Malaria and other parasitic diseases

Christopher King, M.D., Ph.D.

2:15 pm

Discussion

2:45 pm

Break

Session 7:
Special concerns about safety with neonatal vaccination: understanding causality and coincidence

Christopher Wilson, M.D.

3:00 pm

Immune tolerance/deviation

Christopher Wilson, M.D.

3:30 pm

Autoimmunity

Paul-Henri Lambert, M.D.

4:00 pm

Asthma, atopy, and other allergic diseases

Patrick Holt, D.Sc, FRCPath, FAA

4:30 pm

Sudden infant death syndrome and neurological disorders

Marie Griffin, M.D., MPH

5:00 pm

Discussion

5:30 pm - 6:00 pm

Poster viewing

Thursday, March 4, 2004

Speakers

7:00 am

Registration

Session 8:
Potential strategies and barriers to implementing neonatal vaccination–the hepatitis B experience

Regina Rabinovich, M.D., MPH;
Steve Black, M.D.

8:00 am

Industrialized countries

Thomas Saari, M.D.

8:30 am

Developing countries

Mark Kane, M.D., MPH

9:00 am

Discussion

9:30 am

Break

Session 9:
Evaluating neonatal vaccines: regulatory, academic, industry perspectives

Marion Gruber, Ph.D.
Barbara Howe, M.D.

9:45 am

Case study. Neonatal vaccination against pertussis: an industry perspective

Hugues Bogaerts, M.D.

10:15 am

Case study. Neonatal vaccination against RSV: an industry perspective

William Gruber, M.D.

10:45 am

Round table discussion of case studies (academia, industry, FDA)

* Hugues Bogaerts, M.D.; Michael Decker, M.D., MPH;
Joel Ward, M.D.; William Gruber, M.D.;
Rino Rappuoli, Ph.D; Karen Goldenthal, M.D.

Kathryn Edwards, M.D. & panel*

11:15 am

New technologies to optimize neonatal immune responses... next steps

Regina Rabinovich, M.D., MPH

11:45 am

Adjourn